Pharmacogenetics of the local thrombolysis in patients with deep vein thrombosis;Farmakogenetyka celowanego leczenia trombolitycznego u chorych z zakrzepica̧ żył głȩbokich kończyn dolnych

Polskie Archiwum Medycyny Wewnetrznej

Volumn 114, Issue 1, 2005, Pages 644-651

  Falkowski, Aleksander ^a   Kaczmarczyk, Mariusz ^b   Gora̧cy, Iwona ^b   Górecka Szyld, Barbara ^a   Poncyljusz, Wojciech ^c   Parczewski, Miłosz ^b   Ciechanowicz, Andrzej ^b  

^a Katedra I Zak ad Radiologii Ogólnej I Stomatologicznej Pomorskiej AM   (Poland)

^b Katedra Biochemii Klinicznej I Diagnostyki Laboratoryjnej Pomorskiej Akademii   (Poland)

^c Zakład Diagnostyki Obrazowej I Radiologii Interwencyjnej ^*

Author keywords

Deep vein thrombosis; Local thrombolysis; Pharmacogenetics; Streptokinase

Indexed keywords

BLOOD CLOTTING FACTOR 5; FIBRINOGEN; FIBRINOGEN ALPHA; FIBRINOGEN BETA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR; FIBRINOLYTIC AGENT;

ALLELE; ARTICLE; BLOOD CLOT LYSIS; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DNA POLYMORPHISM; DRUG EFFICACY; FEMALE; GENE DELETION; GENE INSERTION; GENOTYPE; HUMAN; LEG THROMBOSIS; MALE; PHARMACOGENETICS; PREVALENCE; RECANALIZATION; UNSPECIFIED SIDE EFFECT; ADULT; AGED; GENETIC POLYMORPHISM; GENETICS; LEG; MIDDLE AGED; TREATMENT OUTCOME; VEIN THROMBOSIS;

ADULT; AGED; BLOOD COAGULATION FACTORS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LEG; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; STREPTOKINASE; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 33646443876     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kottke-Marchant K.: Genetic polymorphisms associated with venous and arterial thrombosis. Arch. Patol. Lab. Med., 2002, 126, 295.
2. Abdollahi M., Cushman M., Rosendaal F.R.: Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb. Haemost., 2003, 89, 493.
3. Lowe G.D.: Venous and arterial thrombosis: epidemiology and risk factors at various ages. Maturitas, 2004, 47, 259.
4. Meissner M.H., Chandler W.L., Elliott J.S.: Venous thromboembolism in trauma: a local manifestation of systemic hypercoagulability? J. Trauma, 2003, 54, 224.
5. Heit J.A., Silverstein M.D., Mohr D.N. i wsp.: The epidemiology of venous thromboembolism in the community. Thromb. Haemost., 2001, 86, 452.
6. Mewissen M.W., Seabrook G.R., Meissner M.H., Cynamon J., Labropoulos N., Haughton S.H.: Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a National Multicenter Registry. Radiology, 1999, 21, 39
7. Semba C.P., Razavi M.K., Kee S.T., Sze D.Y., Dake M.D.: Thrombolysis for lower extremity deep venous thrombosis. Tech. Vasc. Interv. Radiol., 2004, 7, 68.
8. Egeberg O.: Inherited antithrombin deficiency causing thrombophilia. Thromb. Diath. Haemorrh., 1965, 13, 516.
9. Griffin J.H., Evatt B., Zimmerman T.S., Kleiss A.J., Wideman C.: Deficiency of protein C in congenital thrombotic disease. J. Clin. Invest., 1981, 68, 1370.
10. Comp P.C., Nixon R.R., Cooper M.R. Esmon C.T.: Familial protein S deficiency is associated with recurrent thrombosis. J. Clin. Invest., 1984, 74, 2082.
11. Koster T., Rosendaal F.R., Reitsma P.H., van der Velden P.A., Briet E., Vandenboruck J.P.: Factor VII and fibrinogen levels as risk factors for venous thrombosis; a case-control study of plasma levels and DNA polymorphisms: the Leiden Thrombophilia Study (LETS). Thromb. Haemost., 1994, 71, 719.
12. van der Bom J.G., Knijff P. de, Haverkate F. i wsp.: Tissue type plasminogen activator and risk of myocardial infarction. The Rotterdam Study. Circulation, 1997, 95, 2623.
13. Sartori M.T., Danesin C., Saggiorato G. i wsp.: The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin. Appl. Thromb. Hemost., 2003, 9, 299.
14. Lahiri D.K., Bye S., Nurnberger Jr. J.I., Hodes M.E., Crisp M.: A non-organic and non-enzymatic extraction method gives higher yields of genomic DNA from whole-blood samples than do nine other methods tested. J. Biochem. Biophys. Met., 1992, 25, 193.
15. Blasczyk R., Ritter M., Thiede C. i wsp.: Simple and rapid detection of factor V Leiden by allele-specific PCR amplification. Thromb. Haemost., 1996, 75, 757.
16. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M.: A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood, 1996, 88, 3698.
17. Carter A. M., Catto A. J., Grant P.J.: Association of the β-fibrinogen Thr321Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation, 1999, 99, 2423.
18. Weng X., Cloutier G., Genest J.: Contribution of the -455G/A polymorphism at the β-fibrinogen gene to erythrocyte aggregation in patients with coronary artery disease. Thromb. Haemost., 1999, 82, 1406.
19. Margaglione M., Grandone E., Cappucci G. i wsp.: An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb. Haemost., 1997, 77, 605.
20. Ludwig M., Wohn K.D., Schleuning W.D., Olek K.: Allelic dimorphism in the human tissue-type plasminogen activator (t-PA) gene as a result of an Alu insertion/deletion event. Hum. Genet., 1992, 88, 388.
21. Guo S.W., Thompson E.A.: Performing the exact test of Hardy-Weinberg proportions for multiple alleles. Biometrics., 1992, 48, 361.
22. Nebert D.W.: Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin. Genet., 1999, 56, 247.
23. Kładny J., Szumiłowicz G., Gutowski P., Falkowski A.: Wyniki leczenia trombolitycznego streptokinaza̧ przewlekłej zakrzepicy żył głȩbokich. Pol. Tyg. Lek., 1996, 10-13, 148.
24. Goldhaber S.Z., Buring J.E., Lipnick R.J., Hennekens C.H.: Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am. J. Med., 1984, 76, 393.
25. Ng C., M., Rivera J.O.: Meta-analysis of streptokinase and heparin in deep vein thrombosis. Am. J. Health Syst. Pharm., 1998, 1, 1995.
26. Martin M.: PHLEKO-/PHLEFI-Studien: Zwei Studien uber die Behandlung von Phlebothrombosen mit konservativer und fibrinolytischer therapie. Vasa, 1997, 49, 19.
27. Rogers L.Q., Lutcher C.L.: Streptokinase therapy for deep vein thrombosis: a comprehensive review of the English literature. Am. J. Med., 1990, 88, 389.
28. Semba CP., Dake M.D.: Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis. Radiology, 1994, 189, 487.
29. Standeven K.F., Grant P.J., Carter A.M., Scheiner T., Weisel J.W., Ariens R.A.S.: Functional analysis of the fibrinogen Aa Thr312Ala polymorphism. Effects of fibrin structure and function. Circulation, 2003, 107, 2326.
30. Roldan V., Corral J., Marin F., Riviera J., Vicente V.: Effect of factor XIII Val34Leu polymorphism on thrombolytic therapy in premature myocardial infarction. Thromb. Haemost., 2002, 88, 354.